Enhancement of temozolomide stability by loading in chitosan-carboxylated polylactide-based nanoparticles
Source abstract
Abstract
In the presented work, amphiphilic nanoparticles based on chitosan and carboxy-enriched polylactic acid have been prepared to improve the stability of the pro-drug temozolomide in physiological media by encapsulation. The carrier, with a diameter in the range of 150-180 nm, was able to accommodate up to 800 μg of temozolomide per mg of polymer. The obtained formulation showed good stability in physiological condition and preparation media up to 1 month. Temozolomide loaded inside the carrier exhibited greater stability than the free drug, in particular in simulated physiological solution at pH 7.4 where the hydrolysis in the inactive metabolite was clearly delayed. CS-SPLA nanoparticles demonstrated a pH-dependent TMZ release kinetics with the opportunity to increase or decrease the rate. Mass spectroscopy, UV-Vis analysis, and in vitro cell tests confirmed the improvement in temozolomide stability and effectiveness when loaded into the polymeric carrier, in comparison with the free drug.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Bone Tissue Engineering Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (64)
Show source-provided references
1. Abdelwahed W, Degobert G, Stainmesse S, Fessi H (2006a) Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev 58(15):1688–171310.1016/j.addr.2006.09.017 ↗
2. Abdelwahed W, Degobert G, Fessi H (2006b) A pilot study of freeze drying of poly (epsilon-caprolactone) nanocapsules stabilized by poly (vinyl alcohol): formulation and process optimization. Int J 309(1):178–188
3. Abdelwahed W, Degobert G, Fessi H (2006c) Investigation of nanocapsules stabilization by amorphous excipients during freeze-drying and storage. Eur J Pharm and Biopharm 63(2):87–9410.1016/j.ejpb.2006.01.015 ↗
4. Agarwala SS, Kirkwood JM (2000a) Promising new drugs and combinations. Oncologist 5:144–15110.1634/theoncologist.5-2-144 ↗
5. Agarwala SS, Kirkwood JM (2000b) Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 5(2):144–15110.1634/theoncologist.5-2-144 ↗
6. Allard E, Passirani C, Benoit JP (2009) Convection-enhanced delivery of nanocarriers for the treatment of brain tumours. Biomaterials 30(12):2302–231810.1016/j.biomaterials.2009.01.003 ↗
7. Ananta SJ, Paulmurugan R, Massoud TF (2016) Temozolomide-loaded PLGA nanoparticles to treat glioblastoma cells: a biophysical and cell culture evaluation. Neurol Res 38(1):51–5910.1080/01616412.2015.1133025 ↗
8. Appel EA, Rowland MJ, Loh XJ, Heywood RM, Watts C, Scherman OA (2012) Enhanced stability and activity of temozolomide in primary glioblastoma multiforme cells with cucurbit [n] uril. Chem Comm 48(79):9843–984510.1039/c2cc35131e ↗
9. Bajpai AK, Anjali G (2003) Water sorption behavior of highly swelling (carboxy methylcellulose-gpolyacrylamide) hydrogels and release of potassium nitrate as agrochemical. Carbohydr Polym 53(3):271-27910.1016/S0144-8617(03)00071-7 ↗
10. Bajpai J, Maan GK, Bajpai AK (2012) Preparation, characterization and water uptake behavior of polysaccharide based nanoparticles: swelling behaviour of nanoparticles. Prog Nanotech Nanomater 1:9–17
11. Baker SD, Wirth M, Statkevich P, Reidenberg P, Alton K, Sartorius SE, Donehower RC (1999) Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 5(2):309–317
12. Bowman K, Leong KW (2006) Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomedicine 1(2):117-12810.2147/nano.2006.1.2.117 ↗
13. Cho K, Wang XU, Nie S, Shin DM (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14(5):1310–131610.1158/1078-0432.CCR-07-1441 ↗
14. Chowdhury SK, Laudicina D, Blumenkrantz N, Wirth M, Alton KB (1999) An LC/MS/MS method for the quantitation of MTIC (5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide), a bioconversion product of temozolomide, in rat and dog plasma. J Pharmaceut Biomed 19(5):659–66810.1016/S0731-7085(98)00198-8 ↗
15. Darkes MJ, Plosker GL, Jarvis B (2002) Temozolomide. Am J Cancer 1(1):55–8010.2165/00024669-200201010-00006 ↗
16. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA (1994) NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochem 33(31):9045-905110.1021/bi00197a003 ↗
17. Di Martino A, Sedlarik V (2014) Amphiphilic chitosan-grafted-functionalized polylactic acid based nanoparticles as a delivery system for doxorubicin and temozolomide co-therapy. Int J Pharm 474(1):134–14510.1016/j.ijpharm.2014.08.014 ↗
18. Di Martino A, Kucharczyk P, Zednik J, Sedlarik V (2015) Chitosan grafted low molecular weight polylactic acid for protein encapsulation and burst effect reduction. Int J Pharm 496(2):912–92110.1016/j.ijpharm.2015.10.017 ↗
19. Di Martino A, Pavelkova A, Maciulyte S, Budriene S, Sedlarik V (2016) Polysaccharide-based nanocomplexes for co-encapsulation and controlled release of 5-fluorouracil and temozolomide. Eur J Pharm Sci 92:276–28610.1016/j.ejps.2016.05.001 ↗
20. Dresemann G (2010) Temozolomide in malignant glioma. Onco Targets Ther 3:139–14610.2147/OTT.S5480 ↗
21. Drumright RE, Gruber PR, Henton DE (2000) Polylactic acid technology. Advanced Mmaterials 12(23):1841–184610.1002/1521-4095(200012)12:23<1841::AID-ADMA1841>3.0.CO;2-E ↗
22. El-Sharief AMS, Al-Amri AM, Al-Raqa SY (2006) Halogenated, alkylated and new types of imidazolidine, pyrrolidine, imidazotriazine and thienoimidazole derivatives with biological and antitumor activities. J Sulfur Chem 27(03):245–26310.1080/17415990600631316 ↗
23. Fahr A, Liu X (2007) Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Del 4(4):403–41610.1517/17425247.4.4.403 ↗
24. Fiore D, Jackson AJ, Didolkar MS, Dandu VR (1985) Simultaneous determination of dacarbazine, its photolytic degradation product, 2-azahypoxanthine, and the metabolite 5-aminoimidazole-4-carboxamide in plasma and urine by high-pressure liquid chromatography. Antimicrob Agents Chemother 27(6):977–97910.1128/AAC.27.6.977 ↗
25. Gasmi H et al (2015) Does PLGA microparticle swelling control drug release? New insight based on single particle swelling studies. J Control Release 213:120–12710.1016/j.jconrel.2015.06.039 ↗
26. Ge W, Li D, Chen M, Wang X, Liu S, Sun R (2015) Characterization and antioxidant activity of β-carotene loaded chitosan-graft-poly (lactide) nanomicelles. Carbohydr Polym 117:169–17610.1016/j.carbpol.2014.09.056 ↗
27. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Bromberg JE (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–100310.1056/NEJMoa043331 ↗
28. Huang S, Wan Y, Wang Z, Wu J (2013) Folate-conjugated chitosan–polylactide nanoparticles for enhanced intracellular uptake of anticancer drug. JNR 15(12):1–15
29. Jain DS, Athawale RB, Bajaj AN, Shrikhande SS, Goel PN, Nikam Y, Gude RP (2014) Unraveling the cytotoxic potential of Temozolomide loaded into PLGA nanoparticles. DARU 22(1):1810.1186/2008-2231-22-18 ↗
30. Jakobsen SN, Hardie DG, Morrice N, Tornqvist HE (2001). 5'-AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide riboside. J Biol Chem 14, 276, 50, 46912–4691610.1074/jbc.C100483200 ↗
31. Jeyarama AS, Paulmurugan R, Tarik FM (2016) Temozolomide-loaded PLGA nanoparticles to treat glioblastoma cells: a biophysical and cell culture evaluation. Neurol Res 38(1):51-5910.1080/01616412.2015.1133025 ↗
32. Juillerat-Jeanneret L (2008) The targeted delivery of cancer drugs across the blood–brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov Today 13(23):1099–110610.1016/j.drudis.2008.09.005 ↗
33. Kim H, Likhari P, Parker D, Statkevich P, Marco A, Lin CC, Nomeir AA (2001) High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma. J Pharm Biomed Anal 24(3):461–46810.1016/S0731-7085(00)00466-0 ↗
34. Koo YEL, Reddy GR, Bhojani M, Schneider R, Philbert MA, Rehemtulla A, Kopelman R (2006) Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliver Rev 58(14):1556–157710.1016/j.addr.2006.09.012 ↗
35. Kucharczyk P, Zednik J, Sedlarik V (2016). Star-shaped carboxyl group functionalized poly(lactic) prepared through polycondensation reaction. Submitted fopr publication to Macromolecular chemistry and Physics 2016- Under revision10.1007/s13233-017-5014-z ↗
36. Kumari A, Yadav SK, Yadav SC (2010) Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 75(1):1–1810.1016/j.colsurfb.2009.09.001 ↗
37. Lagona J, Mukhopadhyay P, Chakrabarti S, Isaacs L (2005) The cucurbit [n] uril family. AngewChem Int Ed 44(31):4844–487010.1002/anie.200460675 ↗
38. Lanz-Landázuri A, García-Alvarez M, Portilla-Arias J, Martínez de Ilarduya A, Patil R, Holler E, Muñoz-Guerra S (2011) Poly (methyl malate) nanoparticles: formation, degradation, and encapsulation of anticancer drugs. Macromol Biosci 11(10):1370–137710.1002/mabi.201100107 ↗
39. Lazzari S, Moscatelli D, Codari F, Salmona M, Morbidelli M, Diomede L (2012) Colloidal stability of polymeric nanoparticles in biological fluids. JNR 14(6):1–10
40. Ling Y, Wei K, Zou F, Zhong S (2012) Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma. Int J Pharm 430(1):266–27510.1016/j.ijpharm.2012.03.047 ↗
41. Lopes IC, de Oliveira SCB, Oliveira-Brett AM (2013) Temozolomide chemical degradation to 5-aminoimidazole-4-carboxamide–electrochemical study. J Electroanal Chem 704:183–18910.1016/j.jelechem.2013.07.011 ↗
42. Lu W, Sun Q, Wan J, She Z, Jiang XG (2006) Cationic albumin–conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res 66(24):11878–1188710.1158/0008-5472.CAN-06-2354 ↗
43. Matosiuk D, Fidecka S, Antkiewicz-Michaluk L, Lipkowski J, Dybala I, Koziol AE (2002) Synthesis and pharmacological activity of new carbonyl derivatives of 1-aryl-2-iminoimidazolidine: part 2. Synthesis and pharmacological activity of 1, 6-diaryl-5, 7 (1H) dioxo-2, 3-dihydroimidazo [1, 2-a][1, 3, 5] triazines. Eur J Med Chem 37(9):761–77210.1016/S0223-5234(02)01408-3 ↗
44. McCarron PA, Hall M (2004) Pharmaceutical nanotechnology. Encycl Nanosci Nanotechnol 8:469-487
45. Meer L, Janzer RC, Kleihues P, Kolar GF (1986) In vivo metabolism and reaction with DNA of the cytostatic agent, 5-(3, 3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC). Biochem Pharmacol 35(19):3243–324710.1016/0006-2952(86)90419-3 ↗
46. Mehare G, Sengodan T, Tamizharasi S, Sivakumar T, Sawarkar S, Piyush CP (2015) Formulation and characterization of pla nanoparticles of temozolomide. EJPMR 2(5):1089-1100
47. Nygren H, Eksborg S (2012) Stability of temozolomide in solutions aimed for oral treatment prepared from a commercially available powder for infusion. Pharm Methods 3:1,1–1,310.4103/2229-4708.97700 ↗
48. Pasparakis G, Bouropoulos N (2006) Swelling studies and in vitro release of verapamil from calcium alginate and calcium alginate–chitosan beads. Int J Pharm 323(1):34–4210.1016/j.ijpharm.2006.05.054 ↗
49. Pikal MJ (2002) Freeze drying. In: Swarbrick J (ed) Encyclopedia of pharmaceutical technology, vol 2. Marcel Dekker, New York, pp 1299–1326
50. Sinha VR, Kumria R (2001) Polysaccharides in colon-specific drug delivery. Int J Pharm 224(1):19–3810.1016/S0378-5173(01)00720-7 ↗
51. Soares PI, Sousa AI, Silva JC, Ferreira IM, Novo CM, Borges JP (2016) Chitosan-based nanoparticles as drug delivery systems for doxorubicin: optimization and modelling. Carbohydr Polym 147:304–31210.1016/j.carbpol.2016.03.028 ↗
52. Srivastava G, Walke S, Dhavale D, Gade W, Doshi J, Kumar R, Doshi P (2016) Tartrate/tripolyphosphate as co-crosslinker for water soluble chitosan used in protein antigens encapsulation. Int J Biol Macromolec 91:381–39310.1016/j.ijbiomac.2016.05.099 ↗
53. Tian XH, Lin XN, Wei F, Feng W, Huang ZC, Wang P, Diao Y (2011) Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int J Nanomedicine 6:445–452
54. Tyndall EM, Draffan AG, Frey B, Pool B, Halim R, Jahangiri S, Thomas J (2015) Prodrugs of imidazotriazine and pyrrolotriazine C-nucleosides can increase anti-HCV activity and enhance nucleotide triphosphate concentrations in vitro. Bioorg Med Chem Lett 25(4):869–87310.1016/j.bmcl.2014.12.069 ↗
55. Wang H, Xu Y, Zhou X (2014a) Docetaxel-loaded chitosan microspheres as a lung targeted drug delivery system: in vitro and in vivo evaluation. Int J Mol Sci 15(3):3519–353210.3390/ijms15033519 ↗
56. Wang Q, Liu P, Liu P, Gong T, Li S, Duan Y, Zhang Z (2014b) Preparation, blood coagulation and cell compatibility evaluation of chitosan-graft-polylactide copolymers. Biomed Mater 9(1):01500710.1088/1748-6041/9/1/015007 ↗
57. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492–50710.1056/NEJMra0708126 ↗
58. Wheelhouse RT, Stevens MF (1993) Decomposition of the antitumour drug temozolomide in deuteriated phosphate buffer: methyl group transfer is accompanied by deuterium exchange. J Chem Soc Chem Comm 15:1177–117810.1039/c39930001177 ↗
59. Win KY, Feng SS (2005) Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26(15):2713–272210.1016/j.biomaterials.2004.07.050 ↗
60. Xu Y, Shen M, Li Y, Sun Y, Teng Y, Wang Y, Duan Y (2015) The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells. Oncotarget 7:15
61. Xu Y, Shen M, Sun Y, Gao P, Duan Y (2016) Nano composite thermo-sensitive gel for paclitaxel and temozolomide co-delivery to glioblastoma cells. J Nanosci Nanotechnol 16(12):12288-1229810.1166/jnn.2016.12958 ↗
62. You J, Li W, Yu C, Zhao C, Jin L, Zhou Y, Wang O (2013) Amphiphilically modified chitosan cationic nanoparticles for drug delivery. JNR 15(12):1–10
63. Zhang H, Gao S (2007) Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro. Int J Pharm 329(1):122–12810.1016/j.ijpharm.2006.08.027 ↗
64. Zhu Y, Liao L (2015) Applications of nanoparticles for anticancer drug delivery: a review. JNN 15(7):4753–477310.1166/jnn.2015.10298 ↗